ReviewJournal of the Endocrine Society2024
Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective.
Review in Journal of the Endocrine Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of variable-dose metformin as adjunctive therapy to insulin in adolescents with type 1 diabetes mellitus: a systematic review and network meta-analysis.BMC endocrine disorders · 2025Pooled it
- Financial Toxicity in Diabetes: The State of What We Know.Current diabetes reports · 2025Pooled it
- Article
- Glycaemic benefits of smart insulin pens in socioeconomically deprived individuals: a single-Centre study.Irish journal of medical science · 2026Observational
- Experiences of Adults With Type 1 Diabetes Using Digital Health Technology for Diabetes Self-Care: Qualitative Study.JMIR diabetes · 2026Article
- Digital Health Interventions in Children and Adolescents With Type 1 Diabetes Mellitus and Their Impact on Clinical and Behavioral Outcomes: Scoping Review.JMIR mHealth and uHealth · 2026Article
- Evaluating Type 1 Diabetes Resources to Improve Awareness and Knowledge of Type 1 Diabetes Within Community Sport Settings.Endocrinology, diabetes & metabolism · 2026Article
- Clinical and socioeconomic determinants of glycaemic control derived from continuous glucose monitoring in adults with type 1 diabetes.Frontiers in endocrinology · 2026Article
- Global challenges in diabetes research and care: which way forward? An appraisal from the EASD Global Council.Diabetologia · 2025Review
- Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions.Diabetes & metabolism journal · 2025Review
- Early Stages of Automated Insulin Delivery.Journal of diabetes science and technology · 2025Review
- Early Stages of Automated Insulin Delivery.Diabetes technology & therapeutics · 2025Review
- Glycemic Control in Children and Adolescents with Type 1 Diabetes: From Challenges to Innovation.Children (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries. This review focuses on disparities in diabetes technology use among adolescents and young adults with T1D, barriers to access and use, and summarizes common themes emerging across countries and regions. We conducted a survey among medical technology manufacturers and physicians in various countries across diverse geographical regions and performed extensive literature searches. Across all countries and regions, economic barriers stand out as the largest and most common barriers, either preventing market penetrance of technology into a country or limiting its access to the individual with diabetes due to high out of pocket costs. Other common barriers include structural or accessibility barriers, such as stringent eligibility requirements by insurance providers, regardless of whether the insurance was private or government-based, and provider/individual level barriers. Based on the evidence presented, we suggest the need for a joint effort involving governments, private health insurers, technology manufacturers, and healthcare providers to address the global disparities of diabetic technology utilization and ensure equitable access for all individuals living with T1D worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.